Patients maintain stable response with no or minimal fluctuations during 3 years of continuous treatment with lebrikizumab during long-term extension trial
Por:
Silverberg, J, Gold, LS, Lio, P, del Rosso, J, Wollenberg, A, Carrascosa, JM, Gallo, G, Ding, YX, Agell, H, Diemert, S and Vestergaard, C
Publicada:
1 feb 2026
Resumen:
Filiaciones:
Silverberg, J:
George Washington Univ, Sch Med & Hlth Sci, George Dept Dermatol, Washington, DC USA
Gold, LS:
Henry Ford Hlth Syst, Dermatol Clin Res, Detroit, MI USA
Lio, P:
Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
del Rosso, J:
JDR Dermatol Res, Las Vegas, NV USA
Wollenberg, A:
Augsburg Univ Hosp, Dept Dermatol & Allergy, Augsburg, Germany
Univ Lubeck, Comprehens Ctr Inflammat Med, Lubeck, Germany
:
Hosp Universitari Germans Trias I Pujol, Dermatol Dept, UAB, IGTP, Badalona, Spain
Gallo, G:
Eli Lilly & Co, Indianapolis, IN USA
Ding, YX:
Eli Lilly & Co, Indianapolis, IN USA
Agell, H:
Almirall, Barcelona, Spain
Diemert, S:
Almirall Hermal GmbH, Hamburg, Germany
Vestergaard, C:
Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
|